- Capital Cube•4 months ago
Click here to see latest analysisOncoSec Medical, Inc. reports financial results for the quarter ended January 31, 2016.AnalysisSummary numbers: Revenues of USD 0 million, Net Earnings of USD -7.04 million.The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.ONCS-US‘s earnings and EBITDA are […] (Read more...) The post OncoSec Medical, Inc. :ONCS-US: Earnings Analysis: Q2, 2016 By the Numbers appeared first on CapitalCube.
- Zacks Small Cap Research•5 months ago
At January 31, 2016, OncoSec had $28.8 million in cash and cash equivalents. In November, 2015, OncoSec closed a registered direct offering with two healthcare focused funds for the purchase of 2,142,860 shares of its common stock at a price of $3.50 and warrants to purchase up to an aggregate of 1,071,430 shares of common stock at an exercise price of $4.50 per share. On June 8, 2015, OncoSec closed a registered direct offering of 2,469,091 shares of its common stock at a price of $5.50 per share.
- Zacks•last year
Heat's (HTBX) oncology candidate, HS-410, has received fast track designation in the U.S. for the treatment of non-muscle invasive bladder cancer.
|Bid||1.32 x 100|
|Ask||3.50 x 200|
|52wk Range||1.36 - 6.94|
|Day's Range||1.71 - 1.80|
|Avg Vol (3m)||156,179|
As of 4:00 PM EDT. Market closed.